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Abstract  
 
Aim 
To audit compliance with the 2011 European Society of Cardiology (ESC) guidelines for prescribing 
antiplatelet and anticoagulant therapy in patients diagnosed with non-ST-elevation acute coronary 
syndromes (NSTE-ACS).  
 
Methods  
Five-month audit at Cardiac Catheterisation Suite, Mater Dei Hospital, Malta. A data collection form for 
inpatients diagnosed with NSTE-ACS was developed, psychometrically evaluated and completed for 
each patient by the investigator. Comparative analysis to assess whether these patients were being 
managed according to the guidelines was undertaken. 
 
Results  
165 patients were recruited; 73% were male, 37% were between 66 and 75 years and 44% were active 
smokers. The most common risk factors for cardiovascular disease in these patients were hypertension 
(27%), dyslipidemia and obesity (both 16%). 41% of the patients underwent a percutaneous coronary 
intervention, either ad hoc (34%) or elective (7%). Compliance to guidelines for prescription of aspirin 
and clopidogrel 300mg loading dose was 95% and 88% respectively. Compliance to guidelines for 
prescription of aspirin and clopidogrel 75mg daily maintenance dose was 97% and 96% respectively. 
Compliance to guidelines for prescription of proton pump inhibitors (PPIs) in patients receiving dual 
antiplatelet therapy (DAPT) was only 19%; 81% of the patients were prescribed omeprazole against 
guideline recommendations. Compliance to guidelines for prescription of anticoagulation therapy was 
95% with respect to prescription of heparin treatment in combination with DAPT. Compliance to 
guidelines for prescription of enoxaparin was 81%. Compliance to guidelines for other antiplatelet and 
anticoagulant drugs recommended in the guidelines, including ticagrelor, prasugrel, glycoprotein IIb/IIIa 
receptor antagonists, fondaparinux and bivalirudin, was not measured. 
  
Conclusions  
Prescription of antiplatelet and anticoagulant therapy for NSTE-ACS in Malta is predominantly in 
accordance with ESC guidelines. Alternative antiplatelet and anticoagulant drugs and PPIs should be 
included in the Maltese hospital formulary to improve NSTE-ACS management in line with guideline 
recommendations. 
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Introduction 
 
The 2011 European Society of Cardiology (ESC) guidelines on the management of 
acute coronary syndromes without persistent ST-elevation (NSTE-ACS)1 define 
fundamental steps regarding pharmacological management in the acute phase of 
NSTE-ACS, including antiplatelet and anticoagulant treatment.  
 
Following diagnosis of an acute coronary syndrome (ACS), the guidelines recommend 
loading and maintenance doses of antiplatelet drugs. Aspirin is strongly recommended, 
with a loading dose (LD) between 150 and 300mg, followed by a maintenance daily 
dose of 75 to 100mg. Aspirin is given in addition to a P2Y12 receptor antagonist, such 
as ticagrelor, clopidogrel or prasugrel. A LD of a P2Y12 receptor antagonist is 
recommended in addition to aspirin. Clopidogrel and ticagrelor are recommended with 
a LD of 300mg and 180mg respectively, followed by 12 months maintenance therapy 
with 75mg and 90mg respectively. Ticagrelor is recommended for all patients with a 
moderate to high risk of ischaemic events, including patients pre-treated with 
clopidogrel. Clopidogrel is recommended for all patients who cannot receive ticagrelor 
or prasugrel. A 600mg LD of clopidogrel is recommended for patients scheduled for an 
invasive strategy when ticagrelor or prasugrel are not an option. Prasugrel is 
recommended in P2Y12 receptor antagonists-naЇve patients, especially diabetics, in 
whom anatomy is known post-angiography and who are proceeding to PCI, unless 
there are contraindications, such as excessive bleeding risk.  
 
For patients on dual antiplatelet therapy (DAPT), addition of a proton pump inhibitor 
(PPI), preferably not omeprazole, is recommended in patients with a history of gastro-
intestinal hemorrhage or peptic ulcer or other risk factors including Helicobacter pylori, 
patients older than 65 years or concurrent use of anticoagulants or steroids. The 
glycoprotein (GP) IIb/IIIa receptor antagonists, abciximab, eptifibatide and tirofiban, are 
recommended as additional antiplatelet therapy in patients already receiving DAPT 
plus anticoagulants, taking into consideration the risk of ischaemic and bleeding 
complications and before PCI in high-risk patients already on DAPT. The guidelines 
recommend addition of anticoagulation treatment in all patients already on DAPT and 
to continue anticoagulation until hospital discharge. Fondaparinux 2.5mg daily by 
subcutaneous (SC) injection is recommended as having the highest efficacy:safety 
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drug profile and enoxaparin 1mg/kg SC twice daily is recommended when fondaparinux 
is not available. Unfractionated heparin (UFH) is recommended as third choice, if 
fondaparinux and enoxaparin are not available. Bivalirudin is recommended by the 
guidelines together with a GP IIb/IIIa receptor antagonist as an alternative to UFH and 
in patients scheduled for an invasive strategy with a high risk of bleeding.  
 
Aim 
 
To assess compliance with the ESC guidelines for antiplatelet and anticoagulant 
therapy in patients diagnosed with NSTE-ACS at the time of coronary angiography at 
Mater Dei Hospital (MDH) in Malta. 
 
Standards for audit  
 
The European Society of Cardiology (ESC) guidelines for the management of NSTE-
ACS (2011).1 
 
Methods 
 
Approval from the University of Malta Research Ethics Committee was granted. A 
patient data collection form (DCF) was developed and psychometrically evaluated. 
Information collected included patient demographic information, co-morbidities, 
cardiovascular (CV) risk factors, social history, laboratory investigation results and 
prescribed medications. 165 inpatients diagnosed with NSTE-ACS were recruited by 
convenience sampling from the Cardiac Catheterisation Suite, MDH, over a 5-month 
period. The DCF was completed for each patient by reviewing patient treatment files, 
through discussions with consultant cardiologists and nurses and by attending 
procedures performed. Comparative analysis was undertaken and compliance to 
guideline recommendations was categorised into 4 options (Table 1). 
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Table 1: Categorisation of compliance to guideline recommendations 
Categorisation of compliance to guidelines 
1  Drug given, in accordance with guideline recommendations  
2 Drug not given, in accordance with guideline recommendations  
3  Drug given, against guideline recommendations  
4  Drug not given, against guideline recommendations  
 
Results 
 
Patient demographic information  
165 patients were recruited. 73% of the patients were male and 37% of the patients 
were between 66 and 75 years. 44% of the patients were active smokers, 32% of the 
patients had a body mass index (BMI) in the pre-obesity class and 30% of the patients 
had a BMI in obesity class I. The most common risk factors for CV disease were 
hypertension (27%), dyslipidaemia and obesity (both 16%). Following coronary 
angiography, 41% of the patients underwent a PCI, either ad hoc (34%) or elective 
(7%). 
 
Compliance to guidelines for antiplatelet treatment  
Compliance to guidelines for prescription of aspirin 300mg LD at hospital admission 
was 95% (Table 2). Patients who were not given a LD of aspirin in accordance with 
guideline recommendations were already on aspirin therapy and did not require a LD. 
Aspirin LD was not given, against guideline recommendations, in 5% of the patients. 
Reasons for not giving aspirin LD were: risk of bleeding, current meningitis and 
hypersensitivity to aspirin. Compliance to guidelines for prescription of aspirin 75mg 
daily maintenance dose (DD) was 97%. Aspirin daily maintenance dose was given 
against guidelines recommendations in 3% of the patients. These patients had gastro-
oesophageal reflux disease (GORD), haematuria or hypersensitivity to aspirin, 
therefore should not have been prescribed aspirin.  
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Table 2: Compliance to guidelines for aspirin treatment 
Guideline recommendation Categorisation of compliance to guidelines Compliance (%) 
Drug given,  
in accordance with guideline 
recommendations 
46 
Aspirin 300mg  
loading dose (LD) Drug not given,  
in accordance with guideline 
recommendations 
49 
Aspirin 75mg  
maintenance 
daily dose (DD) 
Drug given,  
in accordance with guideline 
recommendations 
97 
 
Compliance to guidelines for prescription of clopidogrel 300mg LD at hospital 
admission was 88% (Table 3). Patients who were not given a LD of clopidogrel in 
accordance with guideline recommendations were already on clopidogrel therapy and 
did not require a LD. No reasons for giving or not giving clopidogrel LD against 
guideline recommendations were documented. In 4 patients scheduled for an invasive 
strategy immediately post-hospital admission, a 600mg LD of clopidogrel was required 
and was given according to guideline recommendations in all patients. Compliance to 
guidelines for prescription of clopidogrel 75mg DD was 96%. No reasons for not giving 
clopidogrel LD, against guideline recommendations (4% of patients) were documented. 
Compliance to guidelines for ticagrelor, prasugrel and GP IIa/IIIb receptor antagonists 
was not measured.  
 
Table 3: Compliance to guidelines for clopidogrel treatment 
Guideline recommendation Categorisation of compliance to guidelines Compliance (%) 
Drug given,  
in accordance with 
guideline recommendations 
74 
Clopidogrel 300mg  
loading dose (LD) Drug not given,  
in accordance with 
guideline recommendations 
14 
Clopidogrel 75mg 
maintenance daily dose (DD) 
Drug given,  
in accordance with 
guideline recommendations 
96 
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Compliance to guidelines for proton pump inhibitors in patients receiving DAPT 
Compliance to guidelines for prescription of PPIs for gastrointestinal protection in 
patients receiving DAPT was only 19%. 81% of the patients were prescribed PPIs 
against guideline recommendations since they were prescribed omeprazole, which is 
preferably not recommended in the guidelines to be given with clopidogrel. 14% of the 
patients were prescribed ranitidine, which is not reported to interact with clopidogrel, 
whilst 5% of the patients were prescribed alternative PPIs (pantoprazole and 
rabeprazole).  
 
Compliance to guidelines for anticoagulant treatment  
Compliance to guidelines for prescription of anticoagulation therapy was 95% with 
regards to prescription of heparin treatment in combination with DAPT, 96% with 
respect to evaluation of ischaemic and bleeding risk and 70% for continuation of 
anticoagulation until hospital discharge. Compliance to guidelines for prescription of 
enoxaparin was 81%. Documented reasons for non-compliance were: not administered 
according to body weight, administered only once daily, bleeding complications and 
UFH or warfarin prescribed instead. Compliance to guidelines for fondaparinux and 
bivalirudin was not measured. 
 
Discussion 
 
This audit assesses whether prescription of antiplatelet and anticoagulant therapy at 
MDH was in accordance with the ESC guidelines. This analysis also identifies reasons 
for management which was not in accordance with the guidelines.  
 
Aspirin and clopidogrel are well recognised as fundamental pharmacological agents in 
the management of NSTE-ACS.1-4 Most of the patients in this audit were managed 
according to guideline recommendations with respect to aspirin therapy, both with 
respect to LD (95%) and DD (97%). Management which was not according to 
guidelines was justified by contra-indications and/or comorbidities, such as bleeding, 
GORD and hypersensitivity.1 With respect to prescription of clopidogrel, the majority of 
patients in this audit were also managed according to guideline recommendations, both 
with respect to LD (88%) and DD (96%).  
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Ten patients were suitable candidates for ticagrelor, however this drug was never 
prescribed since it is not yet available in Malta. These patients were prescribed 
clopidogrel instead. Ticagrelor is recommended in favour of clopidogrel for all patients 
at moderate-high risk of ischaemic events.1 In the PLATO trial, ticagrelor markedly 
reduced death rates from vascular causes, myocardial infarction and death from any 
causes. No significant differences were found in the ticagrelor group compared to the 
clopidogrel group regarding major bleeding events.5  
 
Seventeen patients in this audit were suitable candidates for prasugrel since they were 
diabetic and were scheduled for an invasive strategy. These patients were treated with 
clopidogrel instead since prasugrel is not available on the Maltese Government 
Formulary List (GFL). In the recent TRITON-TIMI 38 trial, prasugrel was found to be 
superior to clopidogrel in reducing death from CV causes and significantly decreasing 
rates of myocardial re-infarction, urgent target-vessel revascularization and stent 
thrombosis. According to literature, major bleeding occurs more frequently in patients 
on prasugrel.6 Studies demonstrating the long-term effects of GP IIb/IIIa receptor 
antagonists are lacking. No patients were prescribed GP IIb/IIIa receptor antagonists 
since they are not yet available in Malta.  
 
A clinically significant interaction with concomitant use of clopidogrel and PPIs, 
especially omeprazole, has been reported.7 Alternative PPIs such as pantoprazole 
have been reported to interact less with clopidogrel.8 81% of the patients in this audit 
were co-prescribed omeprazole, which is the only PPI available on the Maltese GFL. 
Two patients were each prescribed rabeprazole or pantoprazole, both of which are not 
available on the Maltese GFL and were purchased by the patients. 
 
Anticoagulants are considered fundamental in addition to DAPT to inhibit thrombin 
generation and activity, to prevent thrombus formation in NSTE-ACS.1 In this audit, 
anticoagulation treatment was added to DAPT according to guidelines in the majority of 
patients (95%) and most patients (81%) were administered enoxaparin according to 
guidelines. A systematic review of 6 randomised controlled trials comparing enoxaparin 
and UFH in NSTE-ACS shows that enoxaparin has higher efficacy compared to UFH in 
preventing CV death and MI.9  
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Fondaparinux was never prescribed since it is not available in Malta. It is recommended 
by the guidelines as a first choice anticoagulant for NSTE-ACS patients in the absence 
of renal failure.1 In a study by Yusuf et al.10 fondaparinux showed its superiority over 
enoxaparin with respect to the CV outcomes of death, MI or refractory ischaemia at 9 
days, and major bleeding events were also substantially decreased in those patients on 
fondaparinux treatment. Bivalirudin was also never prescribed since it is not yet 
available in Malta. This drug was tested in NSTE-ACS patients in the ACUITY trial, 
where patients on bivalirudin alone had a significantly lower rate of major bleeding.11 
 
Limitations  
 
Guideline recommendations were stringently categorised into whether the drug was 
given or not, according to or against guideline recommendations. Although this 
categorisation was important for data analysis, it was not always easy for the 
investigator to decide on the correct option during data collection. Therefore, some 
assumptions could have led to inaccuracies. Moreover, pharmacological management 
decisions depend on the experience of the consultant taking care of the patient and it 
was not always easy for the investigator to deduce the reason for each management 
decision. Classifying the prescribing action as according to or against guideline 
recommendations may not reflect professional flexibility, therefore strict categorisation 
of borderline cases may also have led to inaccuracies. 
 
Conclusions and recommendations 
 
Prescription of antiplatelet and anticoagulant therapy for NSTE-ACS in Malta is 
predominantly in accordance with ESC guidelines. The main reason for lack of 
compliance to guidelines was that the drug preferred was either not available on the 
Maltese GFL or not even available on the Maltese market. Drugs not on the GFL need 
to be purchased by the patient and since they are relatively expensive, patients are 
reluctant to do so. Additional antiplatelet and anticoagulant drugs and PPIs should be 
included in the Maltese GFL to improve NSTE-ACS management in line with European 
guidelines. 
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